François Guérard
Publications
Publications
Impact of halogen bonding on stability of astatine-211 labelled compounds2èmes Journées scientifiques du GDR Sigma-Hole, Jun 2025, Orsay, France |
|
Evaluation of ligands for rational design of chelators for metallic astatine-2117èmes Journées Scientifiques 2025 du GDR AMI, Jun 2025, Nantes, France |
|
Towards radiolabeling using metallic astatine-211: evaluation of ligands for complexation of At+26th International Symposium on Radiopharmaceutical Sciences, May 2025, Broadbeach, Australia |
|
211At-metal N-Heterocyclic Carbene complexes: a promising alternative for targeted alpha therapy26th International Symposium on Radiopharmaceutical Sciences, May 2025, Broadbeach, Australia |
|
Design of Astatine(I) chelates for applications in targeted alpha therapyJTMS 2025 : Journées "Théorie, Modélisation et Simulation", Nov 2025, Bordeaux, France |
|
Preparation and evaluation of stabilized 211At-labelled aryl compoundsESRR’24 : 21st European Symposium on Radiopharmacy & Radiopharmaceuticals, Apr 2024, Coimbra, Portugal |
|
|
|
Design and evaluation of 211 At metal N-Heterocyclic Carbenes for targeted alpha therapy12th China-Japan-Korea Symposium on Radiopharmaceutical Sciences (CJKSRS 2024), Sep 2024, Kanazawa, Japan |
Stable Astatine-211 labeling assisted by charge-shift bondingRencontres ThéMoSiA-RCTF 2024, Jun 2024, Rouen, France |
|
Molecular modelling towards stable Astatine-211 labelling for targeted alpha therapyPublic event "PRISMAP in Nantes", Sep 2024, Nantes, France |
|
|
|
O-53 Theoretical and experimental study of astatine-metal bonds: towards new 211At-labelling approaches based on transition metal complexesInternational Symposium on Radiopharmaceutical Sciences iSRS 2023, May 2023, Honolulu, United States. pp.108449, ⟨10.1016/j.nucmedbio.2023.108449⟩ |
|
|
O-66 - Preparation of 211At-labeled aromatic compounds from thioarylprecursorsInternational Symposium of radiopharmaceutical sciences, May 2022, Nantes, France |
|
|
P-169 - Influence of radiolysis on astatine-211 chemistryInternational symposium of radiopharmaceutical sciences, May 2022, Nantes, France |
|
|
P-230 - Aryliodonium ylides as efficient precursors for astatine-211 labelingInternational symposium of radiopharmaceutical sciences, May 2022, Nantes, France |
|
|
Targeted alpha-therapy with 211At-anti-mCD138 mAb in a syngeneic murine Multiple Myeloma model : can repeated doses or fractionation protocol overpass single dose efficiency?33rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), European-Association-of-Nuclear-Medicine (EANM), Oct 2020, Virtuel, France. pp.S410-S411, ⟨10.1158/1078-0432.CCR-18-⟩ |
|
|
Synthesis of precursors for 211At-labelling of anti-PSMA HuJ591 mAb and stability comparison after in vitro cellular internalizationISRS 2019, May 2019, PEKIN, China. pp.S69-S70 |
|
|
Advances in the Radiolabeling of Antibodies with Astatine-211 : Toward Simplified Procedures and Improved Radiochemical YieldsTAT 11 INTERNATIONAL SYMPOSIUM, Apr 2019, OTTAWA, Canada. pp.S29 |
Development of innovative probes for the functional exploration of the anti-apoptotic protein Mcl-118th Belgian Organic Synthesis Symposium (BOSS), Jul 2024, Liege, Belgium |
|
Development of innovative probes for the functional exploration of the anti-apoptotic Mcl-1journée annuelle de l'école doctorale, Jun 2024, Tours, France |
|
|
Radiolabeling Chemistry with Heavy Halogens Iodine and AstatineBiomedical Sciences, Online ahead of print, 2021 |
|
|
New Advances in Radioimmunotherapy for the Treatment of CancersBench to Bedside Immunotherapy of Cancers, ch 29, Springer, pp.563-585, 2020, Cancer Immunology, 978-3-030-50286-7. ⟨10.1007/978-3-030-50287-4_29⟩ |
|
|
Radioimmunotherapy of LymphomasNuclear Medicine Therapy, 2019, ⟨10.1007/978-3-030-17494-1_8⟩ |
|
|
Prospects for Enhancing Efficacy of RadioimmunotherapyResistance to Ibritumomab in Lymphoma, pp.139-153, 2018, ⟨10.1007/978-3-319-78238-6_10⟩ |
Method for Radioiodination or Radioastatination of a biomoleculeFrance, Patent n° : WO 2020/221744 A1. 2020 |
|
Method for Radioioidination OR Radioastatination of a BiomoleculeFrance, Patent n° : 19305563.9 - 1 109. 2019 |
|
Method for synthesizing iodo- or astatoarenes using Diaryliodonium SaltsFrance, Patent n° : WO 2017/089492 A1. 2017 |